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Methods

Rat Cerebral Ischemia
Experiments were randomized, blinded, and performed following institutionally approved protocols. Transient focal ischemia was induced by 90-minute occlusion of the middle cerebral artery in male Wistar rats (280-300 g) under 1.2% isoflurane anesthesia and laser Doppler monitoring. Rectal temperature, blood pressure, pH, and gases were all within normal range. Brain samples were obtained from shams at 3 days and ischemic animals at 1, 3, and 7 days postreperfusion.
Human Stroke Brain Samples
Proof-of-concept data were collected in 1 case-a 77-year-old woman with left middle cerebral artery occlusion, who developed hemorrhagic transformation after thrombolysis and died 77 hours poststroke (approved by Ethics Committee, Hospital Vall d'Hebron, with informed consent, PR(HG)85/04). Samples were immediately fixed with 4% paraformaldehyde and kept at −80°C. On autopsy and macroscopic examination, morphological features and neuroimaging guided brain tissue sampling from ipsilateral and contralateral cortex. Infarct area was delineated by an experienced neuropathologist, and 1 cm 3 of contiguous tissue was obtained as peri-infarct.
Primary Cell Cultures
Primary rat microglia, astrocyte, and neurons were prepared following standard methods (details in the online-only Data Supplement). Microglia or astrocyte conditioned media were collected from cultures without or with 1 μg/mL of LCN2 treatment for 24 hours. Oxygen-glucose deprivation experiments were performed using a humidified incubator chamber (90% N 2 , 5% H 2 , 5% CO 2 , 37°C).
Immunohistochemistry
Rats were transcardially perfused with ice-cold PBS. Immunostaining was performed on fresh-frozen 20-μm coronal sections at −0.8 and −2.8 mm from bregma, representing the maximal infarct area in our models. Brain sections (rat and human) or cultured microglia or astrocytes were probed with primary antibodies against NeuN (Millipore), glial fibrillary acid protein (GFAP; BD for rat brains and cultured astrocytes and Invitrogen for human brain) or Iba1 (Abcam for rat brains and cultured microglia and Wako for human brain). Neuronal staining for LCN2 was confirmed with 3 different antibodies (R&D, Abcam, Bioss). Negative controls without primary antibodies showed no immunoreactivity. LCN2 in rat brains was assessed in peri-infarct fields (magnification, ×200) and contralateral homologous areas.
Protein Measurements
Western blots were performed with primary antibodies against GFAP (BD), vascular endothelial growth factor (Santa Cruz), insulin-like growth factor 1 (Santa Cruz), brain-derived neurotropic factor (BDNF; Santa Cruz), thrombospondin-1 (TSP-1; Neomarkers), synaptophysin (Millipore), synaptotagmin (Synaptic Systems), and post-synaptic density 95 (PSD95; Abcam). LCN2 levels in equal volume of conditioned media collected from neurons, astrocytes, or microglia were detected by Western blot. Interleukin-1β (IL-1β; R&D), IL-10 (eBioscience), and LCN2 (Abcam) in cell culture supernatant or brain tissue lysate were measured by ELISA.
Real-Time Polymerase Chain Reaction
Microglial cells were treated with 1 μg/mL of LCN2 (recombinant rat LCN2 from human embryonic kidney 293 cells, Enzo Life Sciences) for 2 hours. For analysis of inducible NO synthase, CD86, CD206, and arginase 1 mRNA, real-time polymerase chain reaction was performed using TaqMan assays (Applied Biosystems) in triplicates.
Microglia Assays
Cell migration assay kit (Chemicon) was used to analyze microglial migration in the presence or absence of 1 μg/mL of LCN2 after 4-to 24-hour incubation. To assess phagocytosis, microglia were seeded onto 96-well plates (1.0×10 5 cells/well) with vehicle or 1 μg/mL of LCN2 and then were incubated with fluorescein-labeled Escherichia coli K-12 BioParticles (Invitrogen) for 2 hours at 37°C. Experiments were performed with 5 replicates per condition and repeated a minimum of 3 times.
Statistics
Three to five separate experiments were performed for all in vivo and in vitro measurements. Data (mean±SD) were analyzed using t tests, 1-way, or 2-way ANOVA (SPSS version 16.0). Significance was set at P<0.05.
Results
Upregulation of LCN2 in Ischemic Neurons
Rats were subjected to 90 minutes of transient focal cerebral ischemia, and then levels of LCN2 in brain tissue were measured with ELISA at 1, 3, and 7 days. LCN2 levels in the brains of normal sham-operated rats were 1.57±0.2 ng/mg protein (n=4; measured at 3 days after sham surgery). After focal cerebral ischemia, LCN2 began to increase in the ischemic hemisphere on day 1 and by day 3 was significantly elevated by ≈2-fold compared with the contralateral hemisphere ( Figure 1A) . By day 7, LCN2 slowly decreased back to contralateral levels.
To explore the cellular localization of LCN2, we performed multilabel immunostaining on rat brain sections at 3 days after ischemic onset. LCN2-positive cells colocalized with NeuNpositive neurons ( Figure 1B) , and most of the LCN2 signal seemed to be located in cytoplasm ( Figure I in the online-only Data Supplement). The intensity of LCN2 immunoreactivity seemed to be higher in peri-infarct cortical areas. However, no LCN2 signals were detected in GFAP-positive astrocytes or ionized calcium-binding adapter molecule 1 (Iba-1)-positive microglia in both contralateral and ipsilateral hemispheres ( Figure 1C ).
To assess human relevance, we examined LCN2 in postmortem brain sections of a human stroke patient obtained 77 hours after ischemic stroke onset. Cell-specific staining showed colocalization of LCN2 with NeuN-positive neurons in the ipsilateral cortex (Figure 2A) . Compared with the contralateral cortex, the numbers of LCN2-positive cells seemed to be increased, and overall fluorescence intensity was stronger in peri-infarct regions (Figure 2A ). Consistent with the ischemic animal models, no LCN2 signals were detected in GFAP-positive astrocytes or ionized calcium-binding adapter molecule 1 (Iba-1)-positive microglia in contralateral and peri-infarct cortical regions ( Figure 2B ).
Neuronal Release of LCN2 After Oxygen-Glucose Deprivation
To confirm our in vivo finding of LCN2 production by neurons, we measured LCN2 in conditioned media of primary cultured neurons, astrocytes, and microglia before and after oxygen-glucose deprivation. Western blots showed that neuronal release of LCN2 into conditioned media was increased by ≈2.5-fold after oxygen-glucose deprivation for 30 minutes and reoxygenation for 24 hours ( Figure 1D ). In contrast, neither astrocytes nor microglia released LCN2 under normal conditions or after oxygen-glucose deprivation ( Figure 1D ).
Activation of Microglia by LCN2
Our data in rat focal cerebral ischemia and an initial proof-ofconcept validation in a human stroke brain sample suggested that ischemia-endangered neurons upregulate LCN2 after stroke. So, we next asked whether LCN2 can influence glial behavior as hypothesized. ELISA measurements showed that LCN2 levels ranged between 5 and 10 ng/mg protein in ischemic brain tissue from our rat models ( Figure 1A ). Total protein concentrations in rat brain are known to be ≈100 mg/mL. Hence, LCN2 concentrations should be ≈0.5 to 1 μg/mL. Of course, it is not possible to convert in vivo concentrations directly to cell cultures, but these levels were tested as a starting point for our cell culture experiments. When primary rat microglia cultures were treated with these concentrations of LCN2 for 24 hours, normally ramified resting microglia were converted into a long-rod morphology with reductions in peripheral branching ( Figure 3A ). The length of the longest axis of 60 cultured microglial cells from 3 independent experiments was quantified. After 1 μg/mL of LCN2 treatment for 24 hours, the length of microglia significantly extended by ≈60% compared with the nontreated group ( Figure 3A, right) . In addition to these morphological changes, several markers of microglia activation were also examined. Real-time polymerase chain reaction showed that mRNA levels of inducible NO synthase, CD86, and CD206 were unchanged ( Figure 3B ), whereas mRNA level of arginase 1 was significantly increased by LCN2 ( Figure 3B ).
Next, we asked whether LCN2 could change microglial production of key cytokines. LCN2 treatment for 24 hours significantly increased IL-10 release by microglia but did not increase IL-1β levels ( Figure 3C ). Finally, we asked whether LCN2-activated microglia had altered cellular function, as assessed by phagocytosis and migration assays. LCN2-treated microglia showed enhanced phagocytic capacity ( Figure 3D ). But there were no detectable effects on microglia migration ( Figure 3D ).
Activation of Astrocytes by LCN2
LCN2 treatment did not change the morphology and cellular viability of primary cultured astrocytes ( Figure 4A and 4B), but other markers suggestive of more subtle activation were affected. After primary rat astrocyte cultures were treated with LCN2 for 24 hours, Western blots of cell lysates showed that GFAP was significantly increased ( Figure 4C and 4D ). LCN2 also increased the expression of TSP-1 and BDNF but did not change the expression of other growth factors such as vascular endothelial growth factor or insulin-like growth factor 1 ( Figure 4C and 4D) . A, After 1 μg/mL of LCN2 treatment for 24 hours, normal ramified resting microglia converted into a long-rod morphology with reductions in peripheral branching (left), and microglia length was extended (right). **P<0.01 (t test). Bar=50 μm. B, Microglia activation markers were measured with real-time polymerase chain reaction. Treatment with 1 μg/mL of LCN2 for 2 hours rapidly upregulated mRNA levels of arginase 1 (Arg 1) but did not change inducible NO synthase (iNOS), CD86, or CD206. *P<0.05 compared with nontreated group (t test). n=4. C, LCN2 treatment for 24 hours increased interleukin-10 (IL-10) release but did not alter IL-1β levels (ELISA). **P<0.01 compared with control (Cont; 1-way ANOVA). n=4. D, LCN2 increased microglia phagocytosis but did not alter migration. *P<0.05 compared with control (t test). n=5. 
Neuronal Effects of LCN2-Activated Glia
Here, we ask whether LCN2-activated glia may be beneficial toward neurons using conditioned media transfer experiments. Microglia or astrocytes were treated with vehicle or 1 μg/mL of LCN2, and then 24 hours later, conditioned media were collected and added to primary rat neurons, either under normal conditions or after oxygen-glucose deprivation.
Conditioned media from reactive glia or LCN2-treated glia were not directly toxic to normal neurons and did not induce notable changes in their morphology ( Figure II in the onlineonly Data Supplement). However, these media seemed to be neuroprotective against oxygen-glucose deprivation. After 2-hour oxygen-glucose deprivation and 24-hour reoxygenation, neuronal viability significantly decreased by ≈30% ( Figure 5A and 5B). For microglia, normal conditioned media were not neuroprotective, but after activation with LCN2, microglia conditioned media significantly increased neuron survival after oxygen-glucose deprivation ( Figure 5A ). For astrocytes, both normal conditioned media and conditioned media from LCN2-activated astrocytes significantly increased neuron survival after oxygen-glucose deprivation ( Figure 5B ). LCN2 alone in control media was not toxic to normal neurons and had no protective effect on neuronal death induced by oxygen-glucose deprivation ( Figure III in the online-only Data Supplement).
Besides neuroprotection, promotion of neuroplasticity may also be a critical part of neurorecovery. Microglia or astrocyte cultures were treated with vehicle or 1 μg/mL of LCN2, and then 24 hours later, conditioned media were collected and 
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added to primary rat neurons, and after another 48 hours, neuronal lysates were probed for presynaptic and postsynaptic proteins. Conditioned media from normal microglia did not change synaptic proteins. But conditioned media from LCN2-activated microglia significantly upregulated synaptophysin ( Figure 6A ) and PSD95 ( Figure 6C ). Both normal unactivated astrocytes and LCN2-activated astrocytes upregulated synaptophysin ( Figure 6A ) and PSD95 ( Figure 6C ), but only LCN2-activated astrocytes significantly upregulated synaptotagmin ( Figure 6B ).
Discussion
We assessed the idea that LCN2 is released by injured neurons as a help me signal for glial activation. In human stroke brain samples, rat focal cerebral ischemia, and primary neuron cultures, injured neurons upregulated and released LCN2. Directly adding LCN2 to primary microglia and astrocytes activated them. LCN2-activated microglia showed enhanced phagocytosis and released IL-10, whereas LCN2-activated astrocytes released BDNF and TSP-1. Conditioned media from LCN2-activated microglia and astrocytes protected neurons against oxygen-glucose deprivation and upregulated synaptic proteins. Taken together, this combination of human stroke samples, rat models, and cell culture approaches suggests that LCN2 may be a help me signal that is released by ischemically endangered neurons to guide astrocytes and microglia into prorecovery phenotypes ( Figure IV in the online-only Data Supplement).
Reactive responses in glia play a central role in stroke recovery. Traditionally, reactive glia were thought to be deleterious. Reactive astrocytes may form inhibitory glial scars that block neural remodeling. 15 Activated microglia may release neurotoxic factors and free radicals that amplified secondary neuronal death. 16 Recently, however, this relatively simplistic idea has been mostly overturned. Reactive glia are now known to play more nuanced roles and under some conditions may be beneficial. 17, 18 During acute stroke, astrocytes can support glutamate homeostasis and blood-brain barrier function. 19, 20 During delayed phases poststroke, astrocytes may release neurotrophic and angiogenic factors. 21, 22 Astrocytic release of high mobility group box 1 may promote neurovascular remodeling. 23 Production of TSP-1 or tissue plasminogen activator by reactive astrocytes may enhance synaptic and dendritic plasticity. [24] [25] [26] Our results are consistent with this concept. LCN2-activated astrocytes increased their production of BDNF and TSP-1, both of which are beneficial after stroke, 22, 25 and conditioned media from LCN2-activated astrocytes upregulated pre-and postsynaptic proteins on recipient neurons.
Similarly, simplistic profiles cannot be applied to microglia. After stroke, prolonged microglia accumulation can last for weeks, thus potentially contributing to both injury and repair. 27, 28 Selective ablation of proliferating resident microglia worsens neuronal apoptosis and infarction. 29 In contrast, microglial CX3C chemokine receptor 1 deletion in mice promoted a protective inflammatory milieu and protected against ischemia at early time points. 30 More recently, it was found that microglial P2Y12 deficiency protected against global cerebral ischemia in mice. 31 These biphasic effects have led to analogies with peripheral macrophages, where damaging M1 phenotypes are contrasted against beneficial M2 phenotypes. 32 In the central nervous system, the situation may be even more complex, and microglia do not just comprise either classically activated M1 or alternatively activated M2 but instead span the range from deleterious to regulatory to remodeling modes. 32, 33 Our results support this idea. LCN2 activates microglia, but their shape (long-rod morphology with reduced branching) is different from typical morphologies after lipopolysaccharide activation. 34 In LCN2-activated microglia, M1-like markers such as inducible NO synthase and CD86 are not altered, whereas for M2-like markers, CD206 is unchanged and arginase 1 is elevated. In the end, this LCN2-induced phenotype may still be beneficial for stroke recovery. LCN2-activated microglia showed increased phagocytosis which may help with debris cleanup and remodeling 28 and produced IL-10 which has been suggested to be prorecovery, 35 and their conditioned media protected neurons against oxygen-glucose deprivation and upregulated pre-and postsynaptic proteins which may help with neuroplasticity.
Taken together, our findings suggest that LCN2 is released by injured neurons as a help me signal to promote beneficial phenotypes in astrocytes and microglia. However, a few caveats should be kept in mind. First, it is likely that injured neurons produce many other factors that can act as distress signals. For example, in zebrafish brains, damaged neurons release leukotriene C4 that shifts inflammatory cells into a proneurogenic phenotype. 36 In mouse neurons, excitotoxic glutamate triggers the release of soluble fractalkine that promotes microglial phagocytosis of neuronal debris. 37 How LCN2 interacts with other help me signals should be explored. Second, although neurons produce LCN2 in our models of cerebral ischemia, other cell types may produce LCN2 in other models and diseases. For example, reactive astrocytes can produce LCN2 after inflammatory stimulation, 38 in spinal cord injury 39 and multiple sclerosis, 40 or in response to neurodegeneration. 41 A third caveat may be related to the effects of LCN2 per se. In our models that attempt to mimic stroke, LCN2 may serve as a beneficial help me signal. However, under other disease conditions, LCN2 may have other effects. For example, under iron-mediated stress conditions or exposure to higher concentrations for prolonged periods of time, LCN2 may increase cell death in neurons and astrocytes. 38, 41, 42 In macrophages, LCN2 may downregulate proinflammatory cytokines and neutrophil infiltration after Streptococcus pneumoniae infections in mice. 43 Furthermore, neutrophils can also release LCN2 when they invade inflamed tissue, with both good and bad effects. 44 How LCN2 ultimately affects the balance between survival and death in multiple cell types warrants deeper analysis. A fourth limitation involves the question of signaling. LCN2 has 2 receptors, megalin and 24p3R. How these receptors operate should be carefully studied in the future. Finally, it must be acknowledged that the present study only provides proof of principle for this concept of help me signaling. Rigorously understanding how LCN2 or other mediators contribute to the balance between injury and repair in vivo will require rigorous knockout and knock-in experiments in the future.
In conclusion, we used a combination of human stroke samples, in vivo rat models, and cell culture approaches to define a mechanism whereby damaged neurons release LCN2 as a help me distress signal that guides microglia and astrocytes into potentially beneficial prorecovery phenotypes. Additional studies are warranted to dissect this pathway and explore new therapeutic opportunities for augmenting LCN2 or other help me mediators in the remodeling neurovascular unit after stroke.
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Primary astrocyte cultures
Primary astrocyte cultures were prepared from cerebral cortices of 1-day-old neonatal Sprague-Dawley rats using standard methods, as previously described 2, 3 . Briefly, 
Primary neuron cultures
Primary neuron cultures were prepared using standard methods, as previously described 4 . Briefly, pregnant Sprague-Dawley rats were anesthetized and the embryos removed by cesarean section. Cortex or hippocampus were dissected out from the embryonic rat fetuses E16 and E19 respectively, then dissociated, both enzymatically (0.25% trypsin-EDTA) for 15 min at 37°C and mechanically. The single cell suspension was diluted in serum-free neurobasal medium containing 2% B27 supplement and 0.5 mM L-glutamine, and then seeded onto pre-coated plates with poly-D-lysine at 3 x 10 5 cells/ml. The medium was half renewal every 3 days. Neuronal cultures were used for experiments on 8-10 days after seeding.
Oxygen-glucose deprivation
Oxygen-glucose deprivation experiments were performed using a humidified incubator chamber kept at 37°C, which contained an anaerobic gas mixture (90% nitrogen, 5%
hydrogen, and 5% carbon dioxide). To initiate oxygen-glucose deprivation, culture medium was replaced with no glucose DMEM for the indicated time periods. After oxygen-glucose deprivation, cultures were removed from the anaerobic chamber, and medium was replaced with maintenance medium, and recovered for 24hrs in a regular incubator. Control cultures were incubated high glucose DMEM under normoxic conditions for the corresponding duration. To measure LCN2 release in neurons, astrocytes or microglia, primary cultures were subjected to oxygen-glucose deprivation for 30min then reoxygenation for 24hrs. LCN2 levels in equal volume of conditioned media collected from neurons, astrocytes or microglia were detected by Western blot. To detect the neuroprotective effects of LCN2-treated microglia or astrocytes, conditioned media collected from microglia or astrocytes treated with vehicle or 1µg/ml of LCN2 for 24hrs were transferred to neurons subjected to oxygen-glucose deprivation for 2hrs during the reoxygenation and incubated for 24hrs. The volume ratio of conditioned media to neurobasal media was 1:4. We used equivalent concentration of LCN2 (0.2µg/ml) alone as control to exclude the effects directly through LCN2. Neuronal survival was measured by MTT assay at least three times in triplicate. Survival of vehicle-treated normal neurons under normoxia condition was taken as 100%, with values for the other groups being given as a percentage of normoxia neurons.
Supplemental Figures
Supplemental Figure I Most of the LCN2 signal appeared to be located in cytoplasm. However, in some very bright and strong staining cells, LCN2 seemed locate in both of cytoplasm and nucleus. It is possible that this phenomenon is caused by very high expression of LCN2 in these cells thus leading to signal overlap in different cell compartments due to the thickness of brain sections (20µm).
